The current stock price of CVRS is 4.27 null. In the past month the price decreased by -0.23%. In the past year, price increased by 288.18%.
Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company's product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts.
CORINDUS VASCULAR ROBOTICS INC
309 WAVERLEY OAKS ROAD SUITE 105
WALTHAM MA 02452
CEO: Mark J. Toland
Phone: 508-653-3335
Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company's product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts.
The current stock price of CVRS is 4.27 null.
CVRS does not pay a dividend.
CVRS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
CVRS stock is listed on the NYSE Arca exchange.
ChartMill assigns a technical rating of 8 / 10 to CVRS. When comparing the yearly performance of all stocks, CVRS is one of the better performing stocks in the market, outperforming 99.62% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to CVRS. The financial health of CVRS is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months CVRS reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS increased by 13.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -232.04% | ||
| ROA | -82.85% | ||
| ROE | N/A | ||
| Debt/Equity | -1.7 |